Literature DB >> 33522955

FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.

Zhuoying Lin1, Wenjie Huang2, Qin He1, Dongxiao Li1, Zhihui Wang1, Yangyang Feng1, Danfei Liu1, Tongyue Zhang1, Yijun Wang1, Meng Xie1, Xiaoyu Ji1, Mengyu Sun1, Dean Tian1, Limin Xia3.   

Abstract

BACKGROUND: Forkhead box C1 (FOXC1), as a member of the FOX family, is important for promote HCC invasion and metastasis. FOX family protein lays a pivotal role in metabolism. ROS is involved in tumor progression and is associated with the expression of lots of transcription factors. We next explored the mechanism underlying FOXC1 modulating the metabolism and ROS hemostasis in HCC.
METHODS: We used amino acids arrays to verify which metabolism is involved in FOXC1-induced HCC. The kits were used to detect the ROS levels in HCC cells with over-expression or down-expression of FOXC1. After identified the downstream target genes and candidate pathway which regulated by FOXC1 during HCC progression in vitro and in vivo, we used western blot, immunohistochemistry, bisulfite genomic sequencing, methylation-specific PCR, chromatin immunoprecipitation analysis and luciferase reporter assays to explore the relationship of FOXC1 and downstream genes. Moreover, the correlation between FOXC1 and target genes and the correlation between target genes and the recurrence and overall survival were analyzed in two independent human HCC cohorts.
RESULTS: Here, we reported that FOXC1 could inhibit the cysteine metabolism and increase reactive oxygen species (ROS) levels by regulating cysteine metabolism-related genes, cystathionine γ-lyase (CTH). Overexpression of CTH significantly suppressed FOXC1-induced HCC proliferation, invasion and metastasis, while the reduction in cell proliferation, invasion and metastasis caused by the inhibition of FOXC1 could be reversed by knockdown of CTH. Meanwhile, FOXC1 upregulated de novo DNA methylase 3B (DNMT3B) expression to induce DNA hypermethylation of CTH promoter, which resulted in low expression of CTH in HCC cells. Moreover, low levels of ROS induced by N-acetylcysteine (NAC) which is an antioxidant inhibited the cell proliferation, migration, and invasion abilities mediated by FOXC1 overexpression, whereas high levels of ROS induced by L-Buthionine-sulfoximine (BSO) rescued the suppression results mediated by FOXC1 knockdown. Our study demonstrated that the overexpression of FOXC1 that was induced by the ROS dependent on the extracellular regulated protein kinases 1 and 2 (ERK1/2)- phospho-ETS Transcription Factor 1 (p-ELK1) pathway. In human HCC tissues, FOXC1 expression was positively correlated with oxidative damage marker 8-hydroxy-2'-deoxyguanosine (8-OHdG), p-ELK1 and DNMT3B expression, but negatively correlated with CTH expression. HCC patients with positive co-expression of 8-OHdG/FOXC1 or p-ELK1/FOXC1 or FOXC1/DNMT3B had the worst prognosis, whereas HCC patients who had positive FOXC1 and negative CTH expression exhibited the worst prognosis.
CONCLUSION: In a word, we clarify that the positive feedback loop of ROS-FOXC1-cysteine metabolism-ROS is important for promoting liver cancer proliferation and metastasis, and this pathway may provide a prospective clinical treatment approach for HCC.

Entities:  

Keywords:  Cystathionine γ-lyase; Cysteine metabolism; DNA methylation; Forkhead box C1; Reactive oxygen species

Year:  2021        PMID: 33522955     DOI: 10.1186/s13046-021-01829-6

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  40 in total

Review 1.  Understanding the Intersections between Metabolism and Cancer Biology.

Authors:  Matthew G Vander Heiden; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis.

Authors:  Ming Yue; Jue Jiang; Peng Gao; Hudan Liu; Guoliang Qing
Journal:  Cell Rep       Date:  2017-12-26       Impact factor: 9.423

Review 3.  Forkhead transcription factors: key players in health and disease.

Authors:  Bérénice A Benayoun; Sandrine Caburet; Reiner A Veitia
Journal:  Trends Genet       Date:  2011-04-18       Impact factor: 11.639

4.  FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal and IGF1 gene regulation.

Authors:  Arunima Sengupta; Vladimir V Kalinichenko; Katherine E Yutzey
Journal:  Circ Res       Date:  2012-11-14       Impact factor: 17.367

Review 5.  The evolution of Fox genes and their role in development and disease.

Authors:  Sridhar Hannenhalli; Klaus H Kaestner
Journal:  Nat Rev Genet       Date:  2009-04       Impact factor: 53.242

Review 6.  FOXO family in regulating cancer and metabolism.

Authors:  Jian Ma; Smita Matkar; Xin He; Xianxin Hua
Journal:  Semin Cancer Biol       Date:  2018-02-02       Impact factor: 15.707

Review 7.  Cancer Metabolism: Current Understanding and Therapies.

Authors:  Jessica L Counihan; Elizabeth A Grossman; Daniel K Nomura
Journal:  Chem Rev       Date:  2018-06-25       Impact factor: 60.622

8.  SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.

Authors:  Vamsi K Kolukula; Geetaram Sahu; Anton Wellstein; Olga C Rodriguez; Anju Preet; Vito Iacobazzi; Gabriella D'Orazi; Chris Albanese; Ferdinando Palmieri; Maria Laura Avantaggiati
Journal:  Oncotarget       Date:  2014-03-15

9.  FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism.

Authors:  Masaji Sakaguchi; Weikang Cai; Chih-Hao Wang; Carly T Cederquist; Marcos Damasio; Erica P Homan; Thiago Batista; Alfred K Ramirez; Manoj K Gupta; Martin Steger; Nicolai J Wewer Albrechtsen; Shailendra Kumar Singh; Eiichi Araki; Matthias Mann; Sven Enerbäck; C Ronald Kahn
Journal:  Nat Commun       Date:  2019-04-05       Impact factor: 14.919

10.  Alteration of amino acid and biogenic amine metabolism in hepatobiliary cancers: Findings from a prospective cohort study.

Authors:  Magdalena Stepien; Talita Duarte-Salles; Veronika Fedirko; Anne Floegel; Dinesh Kumar Barupal; Sabina Rinaldi; David Achaintre; Nada Assi; Anne Tjønneland; Kim Overvad; Nadia Bastide; Marie-Christine Boutron-Ruault; Gianluca Severi; Tilman Kühn; Rudolf Kaaks; Krasimira Aleksandrova; Heiner Boeing; Antonia Trichopoulou; Christina Bamia; Pagona Lagiou; Calogero Saieva; Claudia Agnoli; Salvatore Panico; Rosario Tumino; Alessio Naccarati; H B As Bueno-de-Mesquita; Petra H Peeters; Elisabete Weiderpass; J Ramón Quirós; Antonio Agudo; María-José Sánchez; Miren Dorronsoro; Diana Gavrila; Aurelio Barricarte; Bodil Ohlsson; Klas Sjöberg; Mårten Werner; Malin Sund; Nick Wareham; Kay-Tee Khaw; Ruth C Travis; Julie A Schmidt; Marc Gunter; Amanda Cross; Paolo Vineis; Isabelle Romieu; Augustin Scalbert; Mazda Jenab
Journal:  Int J Cancer       Date:  2015-08-21       Impact factor: 7.396

View more
  4 in total

1.  Low-level EFCAB1 promoted progress by upregulated DNMT3B and could be as a potential biomarker in lung adenocarcinoma.

Authors:  Xiang Yang; Wenjing Shi; Xiaolou Huang; Lijuan Hu; Junjun Wang; Fan Zhang; Yumin Wang; Kate Huang
Journal:  J Clin Lab Anal       Date:  2021-12-14       Impact factor: 2.352

2.  Low-level gastrokine 2 promoted progress of NSCLC and as a potential biomarker.

Authors:  Xiang Yang; Wenjing Shi; Huixin Zhou; Xiaolou Huang; Lijuan Hu; Jiang Feng; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2021-12-30       Impact factor: 2.352

3.  Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.

Authors:  Thong Ba Nguyen; Duy Ngoc Do; Thuy T P Nguyen; Truc Ly Nguyen; Tung Nguyen-Thanh; Ha Thi Nguyen
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.752

4.  A miR-212-3p/SLC6A1 Regulatory Sub-Network for the Prognosis of Hepatocellular Carcinoma.

Authors:  Dan-Dan Zhang; Wen-Er Wang; Yu-Shui Ma; Yi Shi; Jie Yin; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Da Fu; Wen-Jie Zhang
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.